Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Abstract: The present invention provides new prodrugs of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Abstract: A video hosting service stores and provides video content to a client via a network. Advertisers search for videos to target by entering search criteria into a user interface. Advertisers can search based on characteristics of the audience (viewers) of the videos, such as age range, gender, and interests of the viewers, and/or based on metadata associated with the videos. A set of videos that meet the search criteria is then retrieved. Advertisers can select individual ones of these videos or groups of these videos. The selected videos or groups of videos can be added to a media plan. The items from the media plan can be imported into an advertising campaign management system, wherein the advertiser's ads are associated with the selected videos. Subsequently, viewers who view the selected videos also view the advertiser's ads in connection with the videos.

Abstract: Efficient fuel combustion catalyst delivery device and method are provided. A fuel combustion catalyst delivery device includes a storage vessel that contains a liquid. The liquid includes one or more catalytic materials. The storage vessel is attached to a nebulizer that can convert the liquid to an aerosol to be delivered into an air intake of a combustion zone. The aerosol can accelerate fuel combustion. The storage vessel and the nebulizer are made from materials suitable to be exposed to the liquid and the aerosol. The storage vessel and the nebulizer are also suitable to be placed in proximity to the combustion zone such as an engine compartment so that the aerosol can be delivered into the air intake of the combustion zone easily and effectively. The surfaces of the delivery device exposed to the liquid or the aerosol may be made of corrosion-resistant or inert materials if the liquid is acidic.

Abstract: Efficient and effective fuel combustion catalyst delivery apparatus is disclosed. A fuel combustion catalyst delivery apparatus may include a receptacle containing a material such as a liquid. The liquid may include one or more catalytic materials. The apparatus may further include a vibration pump configured to convert the liquid to an aerosol to be delivered into an intake air of a combustion zone, a pressure equalizer configured to maintain the pressure level of the receptacle at about the same pressure level as that of the intake air of the combustion zone, and a liquid delivery device configured to deliver the liquid to the vibration pump. The apparatus may further include an electronic control module and a mounting bracket or a docking station. The electronic control module may be used to control the vibration pump.